{"id":201630,"date":"2026-11-09T14:48:17","date_gmt":"2026-11-09T14:48:17","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/201630\/"},"modified":"2026-11-09T14:48:17","modified_gmt":"2026-11-09T14:48:17","slug":"are-supplements-the-next-big-opportunity-in-glp-1-weight-loss-drug-boom","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/201630\/","title":{"rendered":"Are supplements the next big opportunity in GLP-1 weight-loss drug boom?"},"content":{"rendered":"<p><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/108545657-17942128091794212805-49527577432-1080pnbcnews.jpg\" alt=\"Businesses remain committed to sustainability goals: Novonesis CEO\"\/><\/p>\n<p>Supplements could be the next major sector to benefit from the weight-loss drug boom, Novonesis CEO told CNBC on Monday, as the biosolutions company explores whether microbiome products can help patients on popular GLP-1 medicines.\u00a0<\/p>\n<p>&#8220;We have scientific evidence that [is] going to support the patients [on] GLP-1s feeling better, as a companion during the treatment,&#8221; CEO Ester Baiget told &#8220;Squawk Box Europe,&#8221; referencing an ongoing study with <a href=\"https:\/\/www.cnbc.com\/quotes\/NVO\/\" rel=\"nofollow noopener\" target=\"_blank\">Novo Nordisk<\/a>.<\/p>\n<p>GLP-1 medications and dietary supplements, such as those being developed by Novonesis, could play complementary roles in managing obesity and supporting longer-term health, she argued.\u00a0<\/p>\n<p>While medications can help treat obesity, improving the gut microbiome through nutrition and scientifically backed supplements could support longer-term health, Baiget said. <\/p>\n<p>The microbiome refers to the community of microorganisms, including bacteria, fungi and viruses, that live in or on different parts of the body, particularly in the gut.<\/p>\n<p>Baiget also sees strong commercial demand for supplements with proven health benefits.\u00a0<\/p>\n<p>&#8220;We see that when we prove science with answers, there is a tremendous pull in the market,&#8221; she said. Novonesis is currently studying what Baiget referred to as &#8220;a unique cocktail&#8221; of pro-, pre- and post-biotics to support patients taking GLP-1s made by Wegovy and Ozempic maker Novo Nordisk.\u00a0<\/p>\n<p><a id=\"headline0\"\/>GLP-1s reshape consumer spending<\/p>\n<p>The lucrative weight-loss drugs market pioneered by Novo Nordisk and U.S. rival <a href=\"https:\/\/www.cnbc.com\/quotes\/LLY\/\" rel=\"nofollow noopener\" target=\"_blank\">Eli Lilly<\/a> has had far-reaching consequences beyond health companies.\u00a0<\/p>\n<p>From consumer staples and food companies<a href=\"https:\/\/www.cnbc.com\/2026\/03\/21\/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html\" rel=\"nofollow noopener\" target=\"_blank\"> reassessing meal composition and sizes<\/a>, to fashion companies seeing a <a href=\"https:\/\/www.cnbc.com\/2026\/04\/09\/weight-loss-pills-glp-1s-stitch-fix-apparel-retailers.html\" rel=\"nofollow noopener\" target=\"_blank\">boost from consumers buying new clothes<\/a> after dropping sizes, drugs like Wegovy and Zepbound are widely considered to be reshaping consumer spending across industries.<\/p>\n<p><a href=\"https:\/\/www.pwc.co.uk\/press-room\/press-releases\/research-commentary\/2026\/glp-1-medicines-are-set-to-reshape-uk-consumer-spending--with-th.html\" target=\"_blank\" rel=\"nofollow noopener\">According to a PwC<\/a> survey of U.K. adults, about 70% of GLP-1 users are spending less on snacks, while 40% are spending more on vitamins and supplements. More than 80% of respondents who had now stopped taking the medicine said they maintained some of the dietary changes they adopted while on treatment.<\/p>\n<p>Meanwhile, the global dietary supplements market was valued at an estimated $209.5 billion in 2025 and is projected to more than double to $431.7 billion by 2033, according to <a href=\"https:\/\/www.grandviewresearch.com\/industry-analysis\/dietary-supplements-market-report\" target=\"_blank\" rel=\"nofollow noopener\">Grand View Research<\/a>.<\/p>\n<p>Growing health awareness is driving demand for supplements and functional foods and drinks containing ingredients such as vitamins and probiotics, as consumers seek benefits beyond basic nutrition, the market research firm found.<\/p>\n<p>The global probiotic supplements market was estimated to be worth around $10.5 billion in 2025, growing to $17.5 billion by 2033.<\/p>\n<p><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12693348\/\" target=\"_blank\" rel=\"nofollow noopener\">Some research <\/a>has linked GLP-1 treatment to insufficient protein intake and deficiencies in certain vitamins and minerals, but the extent to which the medications themselves are responsible remains unclear. The microbiome-based products being studied by Novonesis are different from protein and vitamin supplements, and any potential benefit for GLP-1 users has yet to be established.<\/p>\n<p><a id=\"headline1\"\/>Headwinds for human health<\/p>\n<p>For Novonesis, if benefits are scientifically proven, it could be a welcome boost to its human health business, which is currently under pressure. <\/p>\n<p>Its human health business reported an 8%\u00a0<a href=\"https:\/\/backend.novonesis.com\/sites\/default\/files\/document\/2026-11\/Novonesis_2026_27_9M_Interim_report.pdf\" target=\"_blank\" rel=\"nofollow noopener\">decline in organic sales in the third quarter,<\/a> weighed down by weaker demand for probiotic supplements sold through offline channels in North America.\u00a0<\/p>\n<p>The company, formed through the merger of Novozymes and Chr. Hansen in 2024, is a leader in enzymes and microbial solutions used across industries such as food, agriculture, and healthcare. Its products are used in everything from dairy fermentation to dietary supplements.\u00a0<\/p>\n<p>The company holds nearly 50% of the enzymes and cultures market, compared with around 20% for rival International Flavors &amp; Fragrances, according to Morningstar.<\/p>\n<p>Novonesis gets about a third of total sales from the North American market, while Human Health accounts for about 11% of its total sales.<\/p>\n<p><img decoding=\"async\" class=\"InlineVideo-videoThumbnail\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/11\/108324495-2026_EXEC_DECISIONS_YOUTUBE_THUMB_ESTER_BAIGET_1920X1080_CLEAN.jpg\" alt=\"Ester Baiget never planned to be CEO. Then a future bioscience giant came calling\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Supplements could be the next major sector to benefit from the weight-loss drug boom, Novonesis CEO told CNBC&hellip;\n","protected":false},"author":2,"featured_media":201631,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2760,2759,438,1275,1272,700,89493,1741,272,1273,358],"class_list":["post-201630","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotech-and-pharmaceuticals","tag-biotechnology","tag-business","tag-business-news","tag-eli-lilly-and-co","tag-health-care-industry","tag-international-flavors-fragrances-inc","tag-medication","tag-novo-nordisk","tag-novo-nordisk-a-s","tag-pharmaceuticals"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117587037638379202","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/201630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=201630"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/201630\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/201631"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=201630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=201630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=201630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}